Abstracts tagged "proteoglycans"

Abstract Number: 59 • 2018 ACR/ARHP Annual Meeting
Elucidating the Expression and Role of Heparan Sulfate Proteoglycan Editing Sulfatases in Human Rheumatoid Arthritis Synovium and a Rat Adjuvant-Induced Arthritis Model
Ruby J. Siegel¹, Solomon A. Agere¹, Anil K. Singh¹ and Salahuddin Ahmed^2,3, ¹Washington State University, Department of Pharmaceutical Sciences, College of Pharmacy, Spokane, WA, ²Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, ³Division of Rheumatology, University of Washington, Division of Rheumatology, School of Medicine, Seattle, WA
Background/Purpose: Syndecans are cell-surface heparan sulfate proteoglycans (HSPGs) that modulate the receptor/ligand binding of chemokines, cytokines, and growth factors in order to facilitate cellular signaling.…
Abstract Number: 962 • 2017 ACR/ARHP Annual Meeting
Role of Syndecans in Cytokine Mediated Inflammation in Rheumatoid Arthritis Synovial Fibroblasts
Solomon Agere¹, Nahid Akhtar¹, David Fox² and Salahuddin Ahmed¹, ¹Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, ²Department of Medicine [Division of Rheumatology], University of Michigan Medical System, Ann Arbor, MI
Background/Purpose: Syndecans (SDCs) are type-I transmembrane proteoglycans that prominently interact with heparan sulfate, extracellular matrix (ECM) components and glycoproteins. The present study was carried out…
Abstract Number: 1930 • 2017 ACR/ARHP Annual Meeting
Interleukin 1β Decreases Capacity for Repair Human Cartilage Lesions By Mesenchymal Stromal Cells on Collagen/Proteoglycan Scaffolds
Clara Sanjurjo-Rodríguez¹, ROCÍO CASTRO-VIÑUELAS², Tamara Hermida-Gómez³, ISAAC FUENTES BOQUETE⁴, Francisco Javier De Toro Santos⁵, Francisco J Blanco⁶ and SILVIA MARIA DÍAZ-PRADO⁴, ¹of Biomedical Sciences, Medicine and Physiotherapy., Cell Therapy and Regenerative Medicine Group. Universidade da Coruña. INIBIC. CIBER-BBN., A CORUÑA, Spain, ²Biomedical Sciences. Medicine and Physiotherapy, Cell Therapy and Regenerative Medicine Group. Universidade da Coruña. INIBIC., A CORUÑA, Spain, ³Rheumatology, INIBIC. Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. CIBER-BBN., A Coruña, Spain, ⁴Biomedical Sciences, Medicine and Physiotherapy, Cell Therapy and Regenerative Medicine Group. Universidade da Coruña. INIBIC. CIBER-BBN., A CORUÑA, Spain, ⁵Reumatology, Cell Therapy and Regenerative Medicine Group. Universidade da Coruña. INIBIC. CIBER-BBN. Complejo Hospitalario Universitario A Coruña (SERGAS)., La Coruña, Spain, ⁶Servicio de Reumatología. Area Genomica. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC), A Coruña, Spain
Background/Purpose: There is controversy about the effect of catabolic cytokines in regenerative medicine. The purpose of this study was to evaluate the effect of interleukin…
Abstract Number: 1443 • 2016 ACR/ARHP Annual Meeting
A Therapeutic Peptide Vaccine Reduces Pro-Inflammatory Responses and Suppresses Arthritis in the Cartilage Proteoglycan G1 Domain-Induced Mouse Model of Rheumatoid Arthritis
Daniel Zimmerman¹, Harold Steiner III¹, Roy Carambula¹, Adrienn Markovics², Alison Finnegan³, Katalin Mikecz² and Tibor Glant⁴, ¹Research and Development, Cellular Immunology, CEL-SCI Corporation, VIENNA, VA, ²Orthopedic Surgery, Rush University Medical Center, Chicago, IL, ³Dept of Medicine, Rush University Med Ctr, Chicago, IL, ⁴Orthopedic Surgery, Rush Med Ctr Cohn Bldg Rm 708, Chicago, IL
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease leading to inflammatory destruction of the peripheral joints. Although pro-inflammatory T helper 1 (Th1) and/or Th17 cell…
Abstract Number: 1914 • 2016 ACR/ARHP Annual Meeting
Immune Recognition of a Novel Citrullinated Epitope of Cartilage Proteoglycan Aggrecan in Mice with Proteoglycan-Induced Arthritis and in Patients with Rheumatoid Arthritis
Adrienn Markovics¹, Timea Ocsko¹, Robert S. Katz², Edit I Buzas³, Tibor T. Glant¹ and Katalin Mikecz¹, ¹Orthopedic Surgery, Rush University Medical Center, Chicago, IL, ²Rush University Medical Center, Chicago, IL, ³Semmelweis University, Budapest, Hungary
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease leading to the inflammatory destruction of synovial joints. Anti-citrullinated protein antibodies (ACPA) are frequently detected in the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].